These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 12708902)

  • 1. Investigations of the immunoglobulin subtype transformation of anti-heparin-platelet factor 4 antibodies during treatment with a low-molecular-weight heparin (clivarin) in orthopedic patients.
    Ahmad S; Bacher HP; Lassen MR; Hoppensteadt DA; Leitz H; Misselwitz F; Walenga JM; Fareed J
    Arch Pathol Lab Med; 2003 May; 127(5):584-8. PubMed ID: 12708902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential prevalence of anti-heparin-PF4 immunoglobulin subtypes in patients treated with clivarin and heparin: implications in the HIT pathogenesis.
    Ahmad S; Untch B; Haas S; Hoppensteadt DA; Misselwitz F; Messmore HL; Walenga JM; Fareed J
    Mol Cell Biochem; 2004 Mar; 258(1-2):163-70. PubMed ID: 15030181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effects of clivarin and heparin in patients undergoing hip and knee surgery for the generation of anti-heparin-platelet factor 4 antibodies.
    Ahmad S; Haas S; Hoppensteadt DA; Lietz H; Reid U; Bender N; Messmore HL; Misselwitz F; Bacher P; Gaikwad BS; Jeske WP; Walenga JM; Fareed J
    Thromb Res; 2002 Oct; 108(1):49-55. PubMed ID: 12586132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence, isotype, and functionality of antiheparin-platelet factor 4 antibodies in patients treated with heparin and clinically suspected for heparin-induced thrombocytopenia. The pathogenic role of IgG.
    Untch B; Ahmad S; Jeske WP; Messmore HL; Hoppensteadt DA; Walenga JM; Lietz H; Fareed J
    Thromb Res; 2002 Jan; 105(2):117-23. PubMed ID: 11958801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a non-human primate sub-clinical model of heparin-induced thrombocytopenia: platelet responses to human anti-heparin-platelet factor 4 antibodies.
    Untch B; Ahmad S; Messmore HL; Schultz CL; Ma Q; Hoppensteadt DA; Walenga JM; Fareed J
    Thromb Res; 2002 Apr; 106(2):149-56. PubMed ID: 12182915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin-induced thrombocytopenia.
    Juhl D; Eichler P; Lubenow N; Strobel U; Wessel A; Greinacher A
    Eur J Haematol; 2006 May; 76(5):420-6. PubMed ID: 16466367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes.
    Greinacher A; Juhl D; Strobel U; Wessel A; Lubenow N; Selleng K; Eichler P; Warkentin TE
    J Thromb Haemost; 2007 Aug; 5(8):1666-73. PubMed ID: 17488345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-PF4-heparin immunoglobulin G is the major class of heparin-induced thrombocytopenia antibody: findings of an enzyme-linked immunofiltration assay using membrane-bound hPF4-heparin.
    Vun CM; Evans S; Chesterman CN
    Br J Haematol; 2001 Jan; 112(1):69-75. PubMed ID: 11167786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need?
    Warkentin TE; Sheppard JA; Moore JC; Moore KM; Sigouin CS; Kelton JG
    J Lab Clin Med; 2005 Dec; 146(6):341-6. PubMed ID: 16310517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serotonin-release assay-positive but platelet factor 4-dependent enzyme-immunoassay negative: HIT or not HIT?
    Warkentin TE; Smythe MA; Ali MA; Aslam N; Sheppard JI; Smith JW; Moore JC; Arnold DM; Nazy I
    Am J Hematol; 2021 Mar; 96(3):320-329. PubMed ID: 33326124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Levels of antiplatelet factor 4-heparin antibodies and 4T score for heparin induced thrombocytopenia].
    Martinuzzo ME; Cerrato GS; Iglesias Varela ML; Adamczuk YP; Pombo G; Forastiero RR
    Medicina (B Aires); 2012; 72(1):19-22. PubMed ID: 22257451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of heparin-induced thrombocytopenia: a rapid flow cytometric assay for direct demonstration of antibody-mediated platelet activation.
    Tomer A; Masalunga C; Abshire TC
    Am J Hematol; 1999 May; 61(1):53-61. PubMed ID: 10331512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and clinical relevance of anti-platelet factor 4/heparin antibodies before cardiac surgery.
    Selleng S; Malowsky B; Itterman T; Bagemühl J; Wessel A; Wollert HG; Warkentin TE; Greinacher A
    Am Heart J; 2010 Aug; 160(2):362-9. PubMed ID: 20691844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving the specificity of the PF4 ELISA in diagnosing heparin-induced thrombocytopenia.
    McFarland J; Lochowicz A; Aster R; Chappell B; Curtis B
    Am J Hematol; 2012 Aug; 87(8):776-81. PubMed ID: 22641378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the humoral immune response in heparin-induced thrombocytopenia.
    Suh JS; Malik MI; Aster RH; Visentin GP
    Am J Hematol; 1997 Mar; 54(3):196-201. PubMed ID: 9067497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of heparin-platelet factor 4-IgG antibodies improves diagnosis of heparin-induced thrombocytopenia.
    Lindhoff-Last E; Gerdsen F; Ackermann H; Bauersachs R
    Br J Haematol; 2001 Jun; 113(4):886-90. PubMed ID: 11442479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased prevalence of antiheparin platelet factor 4 antibodies in patients may be due to contaminated heparin.
    Adiguzel C; Bansal V; Litinas E; Cunanan J; Iqbal O; Nelson K; Kannan M; Hoppensteadt D; Fareed J
    Clin Appl Thromb Hemost; 2009; 15(2):145-51. PubMed ID: 19357103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beneficial effect of exogenous platelet factor 4 for detecting pathogenic heparin-induced thrombocytopenia antibodies.
    Vayne C; Guery EA; Kizlik-Masson C; Rollin J; Bauters A; Gruel Y; Pouplard C
    Br J Haematol; 2017 Dec; 179(5):811-819. PubMed ID: 29048130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies of the immune response in heparin-induced thrombocytopenia.
    Warkentin TE; Sheppard JA; Moore JC; Cook RJ; Kelton JG
    Blood; 2009 May; 113(20):4963-9. PubMed ID: 19144981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia.
    Amiral J; Wolf M; Fischer A; Boyer-Neumann C; Vissac A; Meyer D
    Br J Haematol; 1996 Mar; 92(4):954-9. PubMed ID: 8616093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.